Innovent Biologics Inc Working Capital to Net Assets Ratio
Innovent Biologics Inc working capital to net assets ratio. Innovent Biologics Inc (6IB) has a Working Capital to Net Assets ratio of 70.4% as of December 2025. Working capital of €13.63 Billion (current assets of €22.01 Billion minus current liabilities of €8.39 Billion) is measured against net assets of €19.36 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Innovent Biologics Inc (2016–2025)
Working capital to net assets ratio of Innovent Biologics Inc from 2016 to 2025. This chart shows how Innovent Biologics Inc's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of December 2025, the ratio stands at 70.4%, reflecting working capital of €13.63 Billion against net assets of €19.36 Billion EUR. See Innovent Biologics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Innovent Biologics Inc Working Capital to Net Assets Ratio by Year (2016–2025)
Innovent Biologics Inc working capital to net assets ratio by year from 2016 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Innovent Biologics Inc from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Innovent Biologics Inc.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 70.4% | €13.63 Billion | €19.36 Billion | €22.01 Billion | €8.39 Billion | ▲ +25.4 pp |
| 2024 | 45.0% | €5.90 Billion | €13.12 Billion | €10.27 Billion | €4.37 Billion | ▼ -26.4 pp |
| 2023 | 71.5% | €8.95 Billion | €12.53 Billion | €13.43 Billion | €4.48 Billion | ▼ -3.2 pp |
| 2022 | 74.6% | €8.01 Billion | €10.73 Billion | €11.51 Billion | €3.50 Billion | ▼ -7.7 pp |
| 2021 | 82.3% | €8.50 Billion | €10.33 Billion | €11.55 Billion | €3.05 Billion | ▼ -8.6 pp |
| 2020 | 90.9% | €7.98 Billion | €8.78 Billion | €9.47 Billion | €1.49 Billion | ▼ -1.9 pp |
| 2019 | 92.8% | €4.41 Billion | €4.76 Billion | €5.46 Billion | €1.04 Billion | ▼ -3.0 pp |
| 2018 | 95.7% | €4.02 Billion | €4.19 Billion | €4.69 Billion | €670.32 Million | ▲ +174.8 pp |
| 2017 | -79.1% | €1.28 Billion | €-1.62 Billion | €1.45 Billion | €163.28 Million | ▲ +108.2 pp |
| 2016 | -187.3% | €1.79 Billion | €-958.22 Million | €1.87 Billion | €76.20 Million | — |